Cell Therapeutics (CTIC -0.7%) says the Gynecologic Oncology Group has informed it that an...


Cell Therapeutics (CTIC -0.7%) says the Gynecologic Oncology Group has informed it that an independent Data Safety Monitoring Board has recommended the continuation of Phase 3 clinical trials of Opaxiotm, a therapy for ovarian cancer, with no changes following a planned interim survival analysis.
From other sites
Comments (2)
  • bonifax
    , contributor
    Comments (36) | Send Message
     
    PIXUVRI

     

    The business began in the last quarter of 2012, but that the effects on sales are not immediate because it is first necessary that the product is registered in each individual country and that is defined and negotiated a code / redemption price, because they are countries with a public health system, in the meantime we started to develop a network of specialized agents, and to "educate" the product. All this makes "non-immediate" effect of Pixuvri in the income statement
    31 Jan 2013, 04:21 PM Reply Like
  • bonifax
    , contributor
    Comments (36) | Send Message
     
    Regardless of the current poor performance on the stock exchange,
    I do not see many companies' sector who have a "pipeline better."
    See PIXUVRI IN STAGE OF MARKETING;
    THE GOOD NEWS ON OPAXIO
    THE GOOD NEWS of PACRITINIB
    On a title you believe it, or, on the contrary, you are totally skeptical
    For the moment I want to believe, hoping to get it right
    31 Jan 2013, 04:22 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs